BioMedical Research LLC — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$1,055,656	100
2024	Research	$207,902	37
2023	Research	$203,124	23
2022	Research	$80,195	24
2021	Research	$318,399	85
2020	Research	$274,071	59
2019	Research	$126,245	25

Breakdown

Who paid Research payments · program years 2019–2025

Pfizer Inc. $1,885,044 310 payments
Teva Pharmaceuticals USA, Inc. $375,048 42 payments
Sanofi Pasteur Inc. $5,500 1 payment

Studies the money was for Research payments · program years 2019–2025

A Phase 3 Randomized Doubleblind 52Week Placebocontrolled Multicenter Study With A Doubleblind 52Week Extension Period With Randomized Dose Updose Down Titration Investigating the Efficacy Safety and Tolerability of Ritlecitinib in Adult Participants With Nonsegmental Vitiligo $435,528 40 payments
A Phase 3 Randomized Activecontrolled Observerblinded Trial to Assess the Safety Tolerability and Immunogenicity of Menabcwy in Healthy Participants 10 to 26 Years of Age $414,437 42 payments
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma $373,411 26 payments
An Interventional Efficacy and Safety Phase 3 Doubleblind 2Arm Study to Investigate Orally Administered Ibuzatrelvir Compared With Placebo in Nonhospitalized Symptomatic Adult and Adolescent Participants With Covid19 Who Are at High Risk of Progressing to Severe Illness $295,012 22 payments
A Phase 2 Randomized Openlabel Trial to Evaluate the Safety and Immunogenicity of A Multivalent Pneumococcal Conjugate Vaccine Given With Or Separately From 13Valent Pneumococcal Conjugate Vaccine in Healthy Infants $168,949 41 payments
A Phase 2B Doubleblind Randomized Placebocontrolled Parallel Group Dose Ranging Study to Evaluate Virological Response and Safety of Oral Pf07817883 in Nonhospitalized Symptomatic Adult Participants With Covid19 $157,769 13 payments
A Phase 3 Randomized Doubleblind Trial to Evaluate the Safety and Immunogenicity of A 20Valent Pneumococcal Conjugate Vaccine in Healthy Infants $128,086 38 payments
A Master Phase 123 Protocol to Investigate the Safety Tolerability and Immunogenicity of Bivalent Bnt162b2 Rna Based Vaccine Candidates in Healthy Children $80,383 20 payments
A Phase 1 Openlabel Agedescending Dosefinding Study and A Phase 23 Placebocontrolled Randomized Doubleblind Study to Evaluate the Safety Tolerability and Immunogenicity of Respiratory Syncytial Virus Prefusion F Subunit Vaccine Rsvpref in Children 2 to 18 Years of Age at High Risk of RSV Disease $57,202 12 payments
A Phase 3 Singlearm Trial to Evaluate the Safety and Immunogenicity of A 20Valent Pneumococcal Conjugate Vaccine in Healthy Children 15 Months Through 17 Years of Age $41,488 18 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.